Arrowstreet Capital, Limited Partnership Rigel Pharmaceuticals Inc Transaction History

Arrowstreet Capital, Limited Partnership

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $324,238 - $490,478	-137,389 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$3.5 - $4.5 $480,861 - $618,250	137,389 New	137,389 $499,000
Q1 2021 May 14, 2021	SELL	$3.35 - $4.93 $4.22 Million - $6.21 Million	-1,260,555 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$2.35 - $3.74 $987,627 - $1.57 Million	-420,267 Reduced 25.0%	1,260,555 $4.41 Million
Q3 2020 Nov 12, 2020	BUY	$1.78 - $4.13 $1.02 Million - $2.38 Million	575,574 Added 52.08%	1,680,822 $4.03 Million
Q2 2020 Aug 12, 2020	BUY	$1.41 - $2.05 $1.56 Million - $2.27 Million	1,105,248 New	1,105,248 $2.02 Million

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $4.2B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.